Viking Therapeutics Inc (VKTX) concluded trading on Wednesday at a closing price of $26.34, with 4.29 million shares of worth about $113.08 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -59.48% during that period and on March 26, 2025 the price saw a loss of about -5.86%. Currently the company’s common shares owned by public are about 111.57M shares, out of which, 108.95M shares are available for trading.
Stock saw a price change of -12.40% in past 5 days and over the past one month there was a price change of -6.99%. Year-to-date (YTD), VKTX shares are showing a performance of -34.54% which decreased to -62.13% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $24.41 but also hit the highest price of $89.10 during that period. The average intraday trading volume for Viking Therapeutics Inc shares is 4.32 million. The stock is currently trading -7.90% below its 20-day simple moving average (SMA20), while that difference is down -14.11% for SMA50 and it goes to -47.34% lower than SMA200.
Viking Therapeutics Inc (NASDAQ: VKTX) currently have 111.57M outstanding shares and institutions hold larger chunk of about 73.46% of that.
The stock has a current market capitalization of $2.96B and its 3Y-monthly beta is at 0.76. It has posted earnings per share of -$1.01 in the same period. It has Quick Ratio of 33.09 while making debt-to-equity ratio of 0.00. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for VKTX, volatility over the week remained 6.80% while standing at 7.49% over the month.
Stock’s fiscal year EPS is expected to drop by -57.98% while it is estimated to decrease by -35.27% in next year.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Scotiabank on February 13, 2025 offering a Sector outperform rating for the stock and assigned a target price of $102 to it. Coverage by Citigroup stated Viking Therapeutics Inc (VKTX) stock as a Neutral in their note to investors on February 07, 2025, suggesting a price target of $38 for the stock. On December 02, 2024, Piper Sandler Initiated their recommendations, while on November 22, 2024, B. Riley Securities Initiated their ratings for the stock with a price target of $109. Stock get a Buy rating from H.C. Wainwright on November 04, 2024.
